PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
Open Access
- 30 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (8), 1408-1417
- https://doi.org/10.1093/ndt/gfaa066
Abstract
Background. The primary challenge of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patient care is the early detection of relapses to prevent organ damage and increase survival. Potential biomarkers for relapses are ANCA and B cells, but their predictive value is a matter of debate. Therefore this study investigated how ANCA and B-cell status related to relapses in AAV patients treated with rituximab (RTX) as remission induction (RI). Methods. This single-centre cohort study identified 110 ANCA-positive AAV patients treated with RTX between 2006 and 2018. Serial ANCA, CD19+ B-cell status and relapses were assessed >2 years. Results. Patients (31/110) relapsed within 2 years after RTX RI treatment. Patients who achieved and maintained PR3-ANCA negativity (n = 29) had few relapses (3%), while persistent proteinase 3 (PR3)-ANCA positivity (n = 49) and reappearance of PR3-ANCAs (n = 10) associated significantly with more relapses (37%, P = 0.002 and 50%, P = 0.002). Patients with incomplete B-cell depletion (n = 11) had significantly more relapses (54%) as compared with patients with B-cell depletion [n = 76 (26%), P = 0.02]. Also, patients with repopulation of B cells (n = 58) had significantly more relapses (41%) as compared with patients without B-cell repopulation [n = 27 (15%), P = 0.03]. Overall, the absence of PR3- or myeloperoxidase (MPO)-ANCA positivity was highly predictive for remaining relapse-free. In PR3-ANCA-positive patients, 96% of the relapses occurred with persistent or reappearance of PR3-ANCAs and 81% with B-cell repopulation. In MPO-ANCA-positive patients, all relapses were restricted to patients with persistent MPO-ANCAs and B-cell repopulation. Conclusions. Upon RI treatment with RTX in AAV patients, ANCA and B-cell status were predictive of the majority of relapses and specifically their absence strongly predicted a relapse-free status. Therefore the implementation of ANCA and B-cell monitoring could guide therapeutic decision-making to prevent relapses in AAV patients treated with RTX.Funding Information
- Dutch Kidney Foundation (KJPB12.028, 17OKG04)
- Clinical Fellowship
- Netherlands Organization for Scientific Research (90713460)
This publication has 39 references indexed in Scilit:
- Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysisRheumatology, 2011
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal VasculitisThe New England Journal of Medicine, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisThe New England Journal of Medicine, 2010
- Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: A data‐driven reviewArthritis & Rheumatism, 2009
- Azathioprine or Methotrexate Maintenance for ANCA-Associated VasculitisThe New England Journal of Medicine, 2008
- Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritisArthritis & Rheumatism, 2008
- Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitisAnnals Of The Rheumatic Diseases, 2008
- Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studiesAnnals Of The Rheumatic Diseases, 2006
- Serial ANCA Determinations for Monitoring Disease Activity in Patients With ANCA-Associated Vasculitis: Systematic ReviewAmerican Journal of Kidney Diseases, 2006
- Serial ANCA titers: Useful tool for prevention of relapses in ANCA-associated vasculitisKidney International, 2003